Federal Trade Commission Statement Concerning Brand Drug ...

FTC Policy Statement Concerning Brand Drug Manufacturers ...

Federal Trade Commission Statement Concerning Brand Drug Manufacturers'. Improper Listing of Patents in the Orange Book. I. Introduction. Brand drug ...

Policy Statement on Brand Pharmaceutical Manufacturers' Improper Listing of Patents in the Food and Drug Administration's 'Orange Book'

FTC Issues Policy Statement on Brand Pharmaceutical ...

“Improper patent listings in the Orange Book illegitimately delay or lock out generic manufacturers from entering the market, depriving ...

The FTC's Criticism of “Junk” Orange Book Filings - Ropes & Gray LLP

Federal Trade Commission, Federal Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange ...

FTC Expands Patent Listing Challenges, Targeting More Than 300 ...

Improper Orange Book patent listings can delay cheaper generic alternatives from entering the market, keeping brand name drug prices ...

FTC Challenges More Than 100 Patents as Improperly Listed in the ...

Today, the Federal Trade Commission (FTC) challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, ...

The Current Status of FTC's Orange Book Listings Challenge

On September 14, 2023, the U.S. Federal Trade Commission issued a "Policy Statement" declaring that "improper" pharmaceutical patent ...

FTC Issues Policy Statement on Patent Listing - Dechert LLP

The FTC claims that improper listings may “block generic competition,” disincentivize investments in competing products, and delay generic drug ...

FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by ...

As detailed in the FTC's amicus brief, when a brand pharmaceutical company lists a patent in the Orange Book it may lead to a statutory stay ...

Improper Orange Book-Listed Patents for AUVI-Q

On September 14, 2023, the Federal Trade Commission (“FTC”) issued a Statement. Concerning Brand Drug Manufacturers' Improper Listing of ...

FTC Warns Pharma Companies It Means Business with Its Orange ...

Actavis). And it is with similar rhetorical excesses that the Commission has begun its latest crusade involving listing on the Food and Drug ...

Policy Statements | Federal Trade Commission

The FTC issues guidance on how the agency applies competition and consumer protection laws.

Improper Orange Book Patent Listings for Seebri and Utibron

1 Federal Trade Commission, Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the. Orange Book (Sept. 14, 2023) ...

FTC warns pharma companies it means business with its Orange ...

Last September, the Federal Trade Commission (FTC) promulgated a “policy statement” entitled “Statement Concerning Brand Drug Manufacturers' ...

FTC Challenges Over 100 Drug Product Patents Listed in FDA ...

To support its position, the FTC cites heavily in the warning letters to a September 14, 2023 FTC Policy Statement Concerning Brand Drug ...

The Federal Trade Commission Put Brand Drug Manufacturers on ...

The Federal Trade Commission (FTC) issued a policy statement on September 14, 2023, stating that “[b]rand drug manufacturers may be harming ...

Food and Drug Administration (FDA) | Federal Trade Commission

Policy Statements · Federal Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book. Date. September 14 ...

The US FTC issues a policy statement declaring that improper ...

On September 14, 2023, the U.S. Federal Trade Commission issued a "Policy Statement" declaring that "improper" pharmaceutical patent ...

Federal Trade Commission Oversight of the Pharmaceutical Industry

In the pharmaceutical sector, the FTC thus has jurisdiction over critical questions. It can police patent abuses and pharmaceutical marketing to ...

FTC Alleges Improper Orange Book Listing of Drug Delivery Device ...

[6] Federal Trade Commission, Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book (Sept. 14, 2023), ...